Compare F5 Inc (FFIV) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Humana Inc — how do they compare? F5 Inc trades at $471.08 (market cap $26.14B), while Humana Inc trades at $450 (market cap $46.49B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.91% dividend while F5 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Humana Inc for 53 Days on average.
| FFIV | HUM | |
|---|---|---|
Market Cap | $26.14B | $46.49B |
Volume | 503,146 | 2,567,704 |
Sector | Technology | Health |
52-Week High | $469.79 | $409.85 |
52-Week Low | $223.99 | $163.67 |
Typical Hold Time | 38 Days | 53 Days |
Enterprise Value | $24.78B | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $466.65, down 0.67% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI readings. The company demonstrates robust fundamentals with revenue growth from $2.7B in 2022 to $3.1B in 2025 and expanding net margins reaching 22.42%. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight competitive positioning.
FFIV presents a mixed outlook with strong earnings beats and profitability offset by premium valuations (P/E 36.78). Analyst consensus leans cautious with 41% buy ratings and $416.60 price target below current levels. Key risks include competitive pressures in application security and potential valuation compression if growth moderates.
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
